Outset Medical, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Outset Medical develops and sells the Tablo Hemodialysis System, an FDA-cleared dialysis platform for hospital, clinic, and home use. The report covers the unaudited three months ended March 31, 2023, compared with the same period in 2022.
Key Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $33.5 million | $30.6 million | 10% |
| Product revenue | $27.8 million | $25.7 million | 8% |
| Service and other revenue | $5.7 million | $4.9 million | 16% |
| Gross profit | $6.4 million | $4.4 million | 45% |
| Gross margin | 19.2% | 14.5% | Up 4.7 percentage points |
| Operating loss | $(43.5) million | $(36.5) million | Loss increased |
| Net loss | $(44.0) million | $(36.9) million | Loss increased |
| Net loss per share | $(0.90) | $(0.78) | Loss per share increased |
| Cash flow from operations | $(44.8) million | $(38.3) million | Use increased |
Operating expenses were $49.9 million, up 22%, including research and development of $13.8 million, sales and marketing of $24.3 million, and general and administrative expense of $11.8 million. Stock-based compensation was $8.5 million, compared with $5.0 million in the prior-year quarter.
At March 31, 2023, cash and cash equivalents were $36.4 million, short-term investments were $212.8 million, and restricted cash was $3.3 million. Total cash, cash equivalents, restricted cash, and short-term investments were $252.5 million. Total liabilities were $146.4 million, including a $100.0 million term loan recorded net of debt discount at $96.5 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased $2.9 million, primarily from higher consumables revenue, growth in the installed console base, higher console revenue, and increased service revenue.
- Gross margin improved from 14.5% to 19.2%, driven primarily by higher average console selling prices and cost-reduction activities. Lower service gross margin partially offset the improvement.
- Operating expenses increased $9.0 million, reflecting higher headcount, compensation and stock-based compensation, infrastructure costs, freight, travel, supplies, and materials.
- Interest income increased to $2.6 million from $0.1 million because of higher interest rates and a higher average investment balance. Interest expense increased to $2.9 million from $0.4 million, primarily because of the new SLR term loan.
- Operating cash use increased to $44.8 million. Cash use reflected the net loss, investment premium amortization, timing of collections and vendor payments, and payment of prior-year bonuses.
- Cash, cash equivalents, and restricted cash declined by $36.8 million during the quarter, compared with a $68.0 million decline in Q1 2022.
Guidance, Outlook, Risks, and Unusual Items
Management expects significant expenses and operating losses to continue in the near term while it invests in growth. The filing does not provide a specific revenue, earnings, or margin forecast. Management states that existing cash, investments, sales proceeds, and available debt financing are expected to fund anticipated needs for at least the next 12 months from the filing date.
- Growth priorities include expanding Tablo adoption in acute-care settings, increasing utilization and fleet expansion at existing customers, and scaling home-based dialysis.
- Management is pursuing gross-margin improvement through manufacturing and cartridge production changes, including increased production in Mexico and continued process efficiencies.
- The company entered into SLR senior secured credit facilities in November 2022. The funded $100.0 million term loan bears interest at term SOFR, subject to a 2.75% floor, plus 5.15%; the rate was 9.81% at March 31, 2023. Principal is generally due November 1, 2027, with interest-only payments permitted through November 2026, subject to conditions.
- The credit facilities are secured by substantially all company assets, including intellectual property, and include financial covenants beginning with the quarter ending December 31, 2023. Covenant breaches or other defaults could accelerate repayment.
- Key risks include continued operating losses and cash burn, the need for future capital, customer adoption and elongated sales cycles, healthcare staffing shortages, hospital budget pressure, supply-chain disruption, component availability, freight costs, manufacturing execution, and the ability to scale the home market.
- Unrealized investment losses of $0.2 million at March 31, 2023 were attributed to interest-rate increases; the company reported no expected credit losses and did not intend or expect to need to sell the affected securities before recovery or maturity.
- The company reported no material pending legal proceedings and no material changes to the risk factors in its 2022 Form 10-K. Internal disclosure controls were assessed as effective at a reasonable assurance level.
Important Facts for Investors to Verify
- Whether revenue growth and installed-base expansion can continue while sales cycles, staffing constraints, and hospital capital scrutiny remain challenging.
- Whether gross-margin improvements from manufacturing and cost-reduction initiatives are sustainable, particularly as service revenue and service costs evolve.
- The pace of cash burn relative to the reported $252.5 million of total cash, investments, and restricted cash, and whether additional financing will be required.
- Compliance with the SLR facility covenants beginning in the fourth quarter of 2023, including required cash balances or revenue and margin thresholds.
- The effect of the $100.0 million term loan, variable interest rates, final fees, prepayment premiums, and secured-collateral provisions on future liquidity.
- Progress in rebuilding and scaling the home dialysis customer pipeline following the 2022 shipment hold and subsequent FDA clearance.